Showing results (181-190 of 209) with videos related to
Sort By:
Pageof 21
Molecular Cancer Therapeutics|July 14, 2026
H3K27M enhances basal ATM signaling but is not required for radiosensitization of diffuse midline glioma via ATM inhibition with AZD1390Erik R Peterson, Leslie A Parsels, Zian Li, et al.Nature Communications|June 24, 2022
Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progressionAndrea Comba, Syed M Faisal, Patrick J Dunn, et al.Neuro-Oncology|May 25, 2007
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitroMarianela Candolfi, G Elizabeth Pluhar, Kurt Kroeger, et al.Science Translational Medicine|March 4, 2016
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in gliomaCarl Koschmann, Anda-Alexandra Calinescu, Felipe J Nunez, et al.The Journal of Clinical Investigation|December 17, 2020
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in micePadma Kadiyala, Stephen V Carney, Jessica C Gauss, et al.Nature Communications|October 19, 2022
P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cellsSree Deepthi Muthukrishnan, Riki Kawaguchi, Pooja Nair, et al.Nature|November 13, 2024
Foundation models for fast, label-free detection of glioma infiltrationAkhil Kondepudi, Melike Pekmezci, Xinhai Hou, et al.The Journal of Clinical Investigation|August 13, 2024
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytomaShashwat Tripathi, Hinda Najem, Corey Dussold, et al.Biorxiv : the Preprint Server for Biology|October 3, 2023
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibYing Pang, Qi Li, Zach Sergi, et al.Iscience|April 17, 2025
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibYing Pang, Qi Li, Zach Sergi, et al.Pageof 21